• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Co-Diovan 160mg/12.5 14 tablets — Made in Spain — Free Delivery

    Co-Diovan 160mg/12.5 14 tablets — Made in Spain — Free Delivery


    Brand: NOVARTIS
    Product Code: Co-Diovan
    Availability: In Stock
    $29.96
    Add to Cart

    Indications

    Hypertension in patients whose blood pressure is not adequately regulated on monotherapy.

    Application

    The recommended dose of co-diovan is 1 tablet 80 mg/12.5 mg/day. with insufficient reduction in blood pressure after 3-4 weeks of treatment, it is recommended to consider continuing treatment at a dose of 1 tablet 160 mg / 12.5 mg / day. 160 mg/25 mg tablets are prescribed for patients who do not achieve sufficient blood pressure reduction when using 160 mg/12.5 mg tablets. if in the future, with the use of tablets 160 mg / 25 mg, blood pressure does not decrease enough, it is recommended to consider the possibility of continuing treatment at a dose of 320 mg / 12.5 mg. 320 mg/25 mg tablets are prescribed to patients who do not achieve sufficient blood pressure reduction when using 320 mg/12.5 mg tablets.
    The maximum daily dose is 320 mg/25 mg.
    The maximum antihypertensive effect is achieved within 2-4 weeks. Some patients may require 4-8 weeks of treatment.
    Co-Diovan can be taken with or without food. Tablets should be taken with a small amount of water.
    In patients with mild to moderate hepatic insufficiency of non-biliary origin and without cholestasis, the dose of valsartan should not exceed 80 mg.

    Contraindications

    Hypersensitivity to any of the components of the preparation co-diovan or to other sulfonamide derivatives. severe liver dysfunction, cirrhosis and cholestasis. anuria, severe renal dysfunction (creatinine clearance 30 ml/min). refractory hypokalemia, hyponatremia, hypercalcemia and symptomatic hyperuricemia.

    Side effects

    Adverse reactions, which were most often reported during clinical trials and laboratory studies during the use of valsartan with hydrochlorothiazide compared with placebo and in individual post-marketing reports, are listed below, depending on the class of organ systems. Undesirable effects that may occur when using each component separately, but which are not noted in clinical trials, may occur during treatment with the combination of valsartan + hydrochlorothiazide.
    Undesirable adverse reactions are presented by frequency: very often (1/10), often (1/100, 1/10), infrequently (1/1000, 1/100), rarely (1/10,000, 1/1000), very rare (1/10,000), unknown (cannot be estimated from the available data). Within each frequency group, adverse reactions are listed in order of decreasing severity.
    The frequency of adverse reactions when using valsartan / hydrochlorothiazide
    Metabolic disorders, metabolism
    Infrequently - dehydration.
    Neurological disorders
    Very rarely - dizziness. Infrequently - paresthesia, confusion, disorientation, nervousness, mood changes, xanthopsia. Unknown - fainting.
    From the organ of vision
    Infrequently - blurred vision.
    From the organ of hearing and vestibular apparatus
    Infrequently - ringing in the ears.
    Vascular disorders
    Infrequently - arterial hypotension.
    From the respiratory system, chest organs and mediastinum
    Infrequently - cough, respiratory distress, pneumonitis. Not known: non-cardiogenic pulmonary edema.
    Gastrointestinal disorders
    Very rarely - diarrhea, thirst, inflammation of the salivary glands, cholecystitis.
    From the side of the musculoskeletal system and connective tissue
    Infrequently - myalgia. Very rarely - arthralgia.
    From the skin and subcutaneous tissue
    Frequency unknown - purpura, toxic epidermal necrolysis, eczema.
    From the side of the heart
    Frequency unknown - heart failure.
    From the hepatobiliary system
    The frequency is unknown - hypochloremic alkalosis, which can induce hepatic encephalopathy or hepatic coma.
    From the urinary system
    Frequency unknown - impaired renal function, interstitial nephritis.
    General disorders and reactions at the injection site
    Infrequently - fatigue, anaphylactic reactions, shock.
    Research
    Not known - increased levels of uric acid, bilirubin and creatinine in blood plasma, hypokalemia, hyponatremia, increased blood urea nitrogen, neutropenia, hyperuricemia, which can provoke gouty attacks in patients with asymptomatic course of the disease, decreased glucose tolerance, which can cause the manifestation of latent diabetes mellitus .
    The following reactions have been observed in clinical trials in patients with hypertension, regardless of their causal relationship to the study preparation: abdominal pain (including upper), anxiety, arthritis, back pain, bronchitis, acute bronchitis, chest pain, dizziness, dyspepsia, shortness of breath, dry mouth, nosebleeds, impotence, gastroenteritis, headache, increased sweating, hypoesthesia, flu, insomnia, sprain, muscle cramps, muscle strain, nausea, nasal congestion, congestion in the paranasal sinuses, pain in the neck, peripheral edema, otitis media, pain in the extremities, rapid heartbeat, pharyngolaryngeal pain, pollakiuria, fever, nasopharyngitis, sinusitis, drowsiness, tachycardia, upper respiratory tract infections, urinary tract infections, vertigo, viral infections, visual disturbances. Whether these effects were causally related to therapy is not known.
    Additional information on individual components
    Adverse reactions that have previously occurred with the use of each component separately may be potential side effects also with the use of Co-Diovan, even if they were not noted in clinical trials or during the post-marketing period.
    The frequency of adverse reactions when using valsartan
    From the blood and lymphatic system
    Not known - decreased hemoglobin, decreased hematocrit, thrombocytopenia.
    From the side of the immune system
    Not known Other hypersensitivity/allergic reactions, including serum sickness.
    Metabolic disorders, metabolism
    Not known - increased plasma potassium levels, hyponatremia.
    From the organ of hearing and vestibular apparatus
    Infrequently - vestibular dizziness.
    Vascular disorders
    Not known - vasculitis.
    Gastrointestinal disorders
    Infrequently - pain in the abdomen.
    From the hepatobiliary system
    Not known - increased liver function tests.
    From the skin and subcutaneous tissue
    Not known - angioedema, rash, itching.
    From the urinary system
    Not known - renal failure.
    The following reactions were reported in clinical trials in patients with hypertension, regardless of their causal relationship with the study preparation: arthralgia, asthenia, back pain, diarrhea, dizziness, headache, insomnia, decreased libido, nausea, edema, pharyngitis, rhinitis, sinusitis , inflammation of the upper respiratory tract, viral infections.
    The frequency of adverse reactions when using hydrochlorothiazide
    Hydrochlorothiazide has been widely used for many years, often at higher doses than those contained in Co-Diovan. The following adverse reactions have been reported in patients taking thiazide diuretics, including hydrochlorothiazide, as monotherapy.
    From the side of metabolism, metabolism
    Very often - when used in high doses, an increase in the level of lipids in the blood; often - hypomagnesemia, hyperuricemia; rarely - hypercalcemia, hyperglycemia, glucosuria and metabolic disorders in patients with diabetes mellitus; very rarely - hypochloremic alkalosis.
    From the blood and lymphatic system
    Rarely - thrombocytopenia, sometimes with purpura; very rarely - agranulocytosis, leukopenia, hemolytic anemia, depression of bone marrow function; unknown - aplastic anemia.
    From the side of the immune system
    Very rarely - hypersensitivity reactions.
    Mental disorders
    Rarely - depression, sleep disturbance.
    Neurological disorders
    Rarely - headache, dizziness, paresthesia.
    From the organ of vision
    Infrequently - blurred vision in the first few weeks after the start of treatment; unknown - acute angle-closure glaucoma.
    Cardiac disorders
    Rarely - cardiac arrhythmia.
    Vascular disorders
    Often - postural hypotension, which may increase with alcohol, the use of anesthetics, sedatives.
    From the respiratory system, chest organs and mediastinum
    Very rarely - respiratory failure, including pneumonia and pulmonary edema.
    Gastrointestinal disorders
    Often - loss of appetite, mild nausea and vomiting; rarely - constipation, gastrointestinal discomfort, diarrhea; very rarely - pancreatitis.
    From the hepatobiliary system
    Rarely - intrahepatic cholestasis or jaundice.
    From the skin and subcutaneous tissue
    Often - urticaria and other types of rash; rarely - photosensitivity; very rarely - necrotizing vasculitis and toxic epidermal necrolysis, skin reactions similar to lupus erythematosus, reactivation of lupus erythematosus of the skin; unknown - erythema multiforme.
    Reproductive system and mammary gland disorders
    Often - impotence.
    From the urinary system
    Not known - acute renal failure, impaired renal function.
    General disorders and reactions at the injection site
    Not known - fever, fatigue.
    From the side of the musculoskeletal system and connective tissue
    Not known - muscle spasms.

    Overdose

    An overdose of valsartan can lead to severe arterial hypotension, which, in turn, can contribute to a decrease in the level of consciousness, the development of heart failure and / or shock.
    With an overdose of hydrochlorothiazide, the following signs and symptoms may occur: nausea, drowsiness, hypovolemia, electrolyte imbalance and, as a result, arrhythmias and muscle spasms. The most characteristic signs and symptoms of overdose are also tachycardia, arterial hypotension, shock, weakness, confusion, dizziness, muscle spasm, paresthesia, exhaustion, mental disorders, vomiting, thirst, polyuria, oliguria, anuria, alkalosis, elevated blood urea nitrogen levels (mainly kidney failure).
    Therapeutic measures depend on the prescription of the overdose, as well as the type and severity of symptoms; at the same time, the primary measure is the normalization of hemocirculation.
    If the preparation  has been recently taken, induce vomiting. If a long time has passed after the use of the preparation, it is necessary to give the patient a sufficient amount of activated charcoal.
    In case of arterial hypotension, the patient should be given a horizontal position and the water-salt balance should be immediately restored by intravenous administration of an isotonic saline solution.
    Valsartan cannot be removed from the body by hemodialysis due to its binding to plasma proteins, but hemodialysis is effective for removing hydrochlorothiazide from the body.

    Storage conditions

    At a temperature not exceeding 30 ° C, in the original packaging to protect against moisture.

    There are no reviews for this product.
    VEV Healthcare Store © 2017